Oramed Pharmaceuticals Inc. balance sheet

At the end of fiscal 2025, Oramed Pharmaceuticals Inc. had total assets of $231m and shareholders' equity of $200m. It held $45.9m in cash against $652,000 of debt: net cash of $45.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Oramed Pharmaceuticals Inc.: balance sheet, annual
Fiscal year	2016Aug 2016	2017Aug 2017	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Cash and equivalents	—	—	—	—	—	—	40	9	46
Total current assets	31	20	31	33	41	95	157	163	133
Total assets	43	39	47	35	45	128	162	221	231
Accounts payable	—	—	—	—	—	—	—	1	0
Deferred revenue (current)	2	2	2	3	3	2	1	—	1
Total current liabilities	4	5	5	5	5	7	6	53	19
Short-term debt	—	—	2	3	—	—	—	51	—
Long-term debt	—	—	11	10	—	13	0	—	—
Total debt	0	0	14	12	—	13	0	51	1
Shareholders' equity	26	19	31	19	33	—	152	164	200
Net debt (negative = net cash)	—	—	—	—	—	—	−40	42	−45
Shares outstanding	13m	14m	17m	17m	24m	35m	40m	40m	39m

US$ millions unless shown otherwise. Fiscal quarters.

Oramed Pharmaceuticals Inc.: balance sheet, quarterly
Quarter	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025
Total current assets	155	151	176	163	131	99	136	133
Total assets	160	156	231	221	148	162	220	231
Accounts payable	—	—	—	1	1	1	1	0
Deferred revenue (current)	—	—	—	—	—	—	—	1
Total current liabilities	5	1	78	53	5	4	6	19
Short-term debt	—	—	75	51	—	—	—	—
Long-term debt	—	—	75	—	—	—	—	—
Total debt	—	—	150	51	—	—	—	—
Shareholders' equity	151	152	149	164	141	155	203	200
Shares outstanding	40m	40m	40m	40m	41m	41m	41m	39m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: KRSA vs ORMP MCRB vs ORMP CLGN vs ORMP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Oramed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Oramed Pharmaceuticals Inc.